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Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in
Atrial Fibrillation Patients and Risk of Dementia: A Nationwide
Propensity-Weighted Cohort Study
Mette Søgaard, DVM, PhD; Flemming Skjøth, MSc, PhD Martin Jensen, MSc; Jette Nordstrøm Kjældgaard, BSc;
Gregory Y. H. Lip, MD; Torben Bjerregaard Larsen, MD, PhD; Peter Brønnum Nielsen, MSc, PhD
Background-—It is unclear whether nonvitamin K antagonist oral anticoagulants (NOACs) can mitigate dementia development in
atrial fibrillation. We compared dementia development among users of NOACs or warfarin in patients with atrial fibrillation with no
prior neurological diagnoses.
Methods and Results-—We conducted a Danish nationwide cohort study including 33 617 new oral anticoagulant users with
nonvalvular atrial fibrillation, of which 11 052 were aged 60 to 69 years, 13 237 were aged 70 to 79 years, and 9238 were aged
80 years and older. To exclude prevalent non-oral anticoagulants–associated dementia, we considered the at-risk population of
patients alive and free of dementia at 180 days following inclusion. We compared rates of new-onset dementia by age and
treatment regimen using inverse probability of treatment weighting to account for confounding. Approximately 60% of patients
were NOAC users and 40% were warfarin users. Mean follow-up was 3.4 years. Dementia occurred in 41 patients aged 60 to
69 years, 276 patients aged 70 to 79 years, and 441 patients aged 80 years and older. Relative to warfarin users, dementia rates
were nonsignificantly lower among NOAC users aged 60 to 69 years (0.11 events/100 person-years versus 0.12 events/100
person-years; weighted hazard ratio, 0.92 [95% CI, 0.48–1.72]) and NOAC users aged 70 to 79 years (0.64 events/100 person-
years versus 0.78 events/100 person-years; weighted hazard ratio, 0.86 [95% CI, 0.68–1.09]), whereas NOACs were associated
with significantly higher dementia rates (2.16 events/100 person-years versus 1.70 events/100 person-years; weighted hazard
ratio, 1.31 [95% CI, 1.07–1.59]) in patients 80 years and older.
Conclusions-—This nationwide cohort of patients with atrial fibrillation revealed no clinically meaningful difference in dementia
development between users of NOACs or warfarin apart from a higher risk in NOAC users 80 years and older, which may relate to
residual confounding from selective prescribing and unobserved comorbidities. ( J Am Heart Assoc. 2019;8:e011358. DOI: 10.
1161/JAHA.118.011358.)
Key Words: anticoagulants • atrial fibrillation • dementia • direct oral anticoagulant • warfarin
A trial fibrillation (AF) is the most common cardiacarrhythmia and is associated with up to a 5-fold
increased risk of stroke.1,2 Owing to the increasing life
expectancy, both prevalence and incidence rates of AF are
projected to increase over the coming decades. Substantial
increases in rates of dementia are also expected given the
strong correlation with age.3
Dementia is a condition that impairs memory and other
cognitive abilities, causing significant disability. Growing evi-
dence suggests an association between AF and dementia even
if no clinical strokes have occurred.4–8 Nevertheless, the
pathological mechanism underlying the association between AF
and dementia is unclear. Plausible mechanisms include AF-
relatedmicroemboli andmicrobleeds and shared risk factors for
AF and dementia such as coronary artery disease, hypertension
and hypotension, heart failure, diabetes mellitus, and age.9
Oral anticoagulant (OAC) therapy with vitamin K antago-
nists (eg, warfarin) or with nonvitamin K antagonist OACs
(NOACs) is central for stroke prevention in AF.10 While
warfarin traditionally has been the mainstay of treatment,
meticulous dosage titration may be necessary to obtain an
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anticoagulation effect within the target therapeutic range
(TTR). If not achieved, the treatment may entail periods of
supratherapeutic and subtherapeutic effects from warfarin,
which can lead to microemboli and microbleeds.11 Indeed,
time outside the TTR in patients with AF receiving warfarin has
been associated with increased risk of dementia6,11
Compared with warfarin, NOACs have a favorable risk-
benefit profile with significant reductions in stroke, in
particular a reduction in intracerebral hemorrhage.12 Because
of the more predictable pharmacokinetics, NOACs may
mitigate the challenges with TTR from dose titration. It is
therefore plausible that NOACs in comparison with warfarin
may prevent silent (or undetected) infarcts and microbleeds,
and consequently may be able to slow the cognitive decline
attributable to AF and AF risk factors. Nevertheless, random-
ized controlled trials that have assessed the efficacy and
safety of NOAC versus warfarin did not include cognitive
function as outcome, and data comparing rates of dementia
among patients with AF treated with warfarin or NOAC are
scarce.13,14
The purpose of this study was to study the effect of an
anticoagulant treatment regimen (NOAC or warfarin) on the
risk of new-onset dementia in clinical practice using a
nationwide Danish cohort of OAC-naive patients with AF with
no prior neurological diagnoses.
Methods
The source population for this cohort study comprised all
citizens of Denmark encompassing 5.6 million inhabitants.
Health care in Denmark is provided through a national tax-
funded system. As a result, data on diagnoses and prescrip-
tion claims are compiled in longitudinal national registries
allowing true nationwide population-based studies. The pre-
sent study utilized linkage between 3 nationwide medical
registries. The first was the National Patient Register,15 which
encompasses information from all inpatient stays and outpa-
tient visits at Danish hospitals, including dates of hospitaliza-
tion and discharge, outpatient clinic visits, surgical
procedures, and discharge International Classification of
Diseases (ICD) diagnoses since 1977. The second registry
was the National Prescription Register,16 which holds data on
all prescription purchases by Danish residents since 1995.
Data include the patients’ civil registration number, date of
dispensing, and type and quantity of drug prescribed. The
third registry was the Danish Civil Person Registry,17 which
contains data on sex, date of birth, and vital and emigration
status. We linked these registries using a unique 10-digit
personal registration number assigned to each Danish citizen
at birth and to residents upon immigration.17
Ethical Considerations and Data Availability
The study was approved by the Danish Data Protection
Agency (reference 2015-57-0001). Registry studies do not
require ethical approval in Denmark. The data were provided
by the Danish Health Data Authority. Because of restrictions
related to Danish law and protecting patient privacy, the
combined set of data as used in this study can only be
made available through the Danish Health Data Authority.18
This state organization holds the data used for this study.
Researchers can apply for access to these data when the
request is approved by the Danish Data Protection
Agency.19
Study Population
We identified all patients 60 years and older with a first-time
prescription redemption of apixaban (introduced December
Clinical Perspective
What Is New?
• Growing evidence suggests an association between atrial
fibrillation (AF) and dementia. It has been hypothesized that
nonvitamin K antagonist oral anticoagulants (OACs) could
play a role in reducing the risk of cognitive impairment and
dementia in patients with AF, but the available evidence is
sparse and equivocal.
• This study investigated a large well-defined, nationwide,
population-based cohort of patients with nonvalvular AF
initiating OAC treatment during 2011 through 2016 and
compared rates of new-onset dementia by age and treat-
ment regimen (nonvitamin K antagonist OACs versus
warfarin).
• Among patients with AF with no prior neurological disorders,
rates of new-onset dementia was nonsignificantly different
among patients initiating nonvitamin K antagonist OAC
therapy versus warfarin.
What Are the Clinical Implications?
• In the absence of disease-modifying treatments for most
forms of dementia, any means to prevent or delay its onset
is of major clinical and social importance.
• This real-world observational study suggests no difference
of nonvitamin K antagonist OACs over well-managed
warfarin therapy.
• However, potential residual confounding related to selective
prescribing and unobserved comorbidities warrants cautious
clinical interpretation, and further studies, including ran-
domized trials, are needed to fully investigate the impact of
OAC treatment in AF on dementia development and
progression.
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10, 2012), dabigatran (introduced August 1, 2011), rivarox-
aban (introduced February 1, 2012), or warfarin (since August
1, 2011, to match the NOAC treatment regimen) who had a
previous hospital AF diagnosis or received an AF diagnosis
within 30 days after prescription redemption. Patients with
edoxaban treatment were not considered because of the late
market entry in the study period. Study patient inclusion was
terminated by December 31, 2016. We did not include
patients with prior experience with any OAC in order to
establish an OAC-naive cohort, as was previously per-
formed.20 We excluded patients who had not been residents
in Denmark for at least 5 years before date of first OAC
prescription redemption to ensure sufficient lookback time for
diagnoses of prevalent dementia as well as comorbidities and
medications. To focus on nonvalvular AF, we excluded
patients with previous diagnoses indicating valvular AF (mitral
stenosis or mechanical heart valves). We further excluded
patients with another indication for OAC treatment (ie, history
of venous thromboembolism within 90 days before prescrip-
tion redemption). Finally, because we were interested in
incident dementia events under OAC treatment exposure, we
excluded patients with previous dementia diagnoses, use of
antidementia medications, or diagnosis of mild cognitive
impairment or an amnestic syndrome, which may represent
prodromal dementia, and patients with previous neurological
diagnoses including ischemic or hemorrhagic stroke, transient
ischemic attack (TIA), or traumatic brain injury before first
OAC prescription redemption.
Definition of Landmark Population, Exposure, and
Follow-Up
To study exposure of OAC treatment and rates of dementia,
we considered the at-risk population of patients who had
purchased a first prescription of an NOAC or warfarin who
were alive and free of dementia at the landmark time point of
180 days following the date of OAC prescription purchase
that led to inclusion in the study. The reasoning underlying
this choice of landmark analysis was to exclude possible
prevalent and non–OAC-associated dementia cases, since
dementia diagnosed shortly after the first OAC prescription is
unlikely to be causally related to the treatment. We used
recent anticoagulant purchase in the landmark population to
determine patients’ anticoagulant therapy (NOAC versus
warfarin). To ensure steady state OAC treatment, patients
were required to fill at least 2 prescriptions of the same type
of OAC during the 180-day landmark period (“extended
anticoagulant usage”), since the typical patient persisting with
therapy would purchase anticoagulants at least twice during
any 6-month period.21 Patients with both warfarin and NOAC
prescriptions during the landmark period were excluded. We
subsequently followed patients from the 180-day landmark
until a diagnosis of dementia, emigration, death, or study end
(March 23, 2018), whichever came first.
Study End Points
The primary study outcome was a composite of incident
dementia subtypes defined by hospital inpatient and outpatient
clinic diagnoses of dementia recorded in the National Patient
Registry from the 180-day landmark. The secondary outcomes
were the specific dementia subtypes (Alzheimer disease,
vascular dementia, and other dementia). The hospital admission
date or start date of outpatient clinic follow-up was considered
the date of dementia diagnosis. In the National Patient Registry,
dementia diagnoses are available for hospital admissions since
1977 and for outpatient visits since 1995.15 The positive
predictive value of inpatient and outpatient diagnoses of all-
cause dementia is 86% and 81% for Alzheimer disease.22
Ascertainment of Comorbidity
Using the patients’ medical history since 1994 (introduction
of ICD-Tenth Revision in Denmark) and medication claims, we
obtained information on comorbidities at the time of OAC
prescription, which could possibly confound the causal
association between choice of OAC treatment for stroke
prevention in nonvalvular AF and risk of new-onset dementia.
Comorbidity information included cardiovascular and meta-
bolic diseases, lifestyle-related diseases, and information on
depression and substance abuse. Table S1 provides informa-
tion on all codes for diagnoses and medications.
We further combined covariate information into the
Charlson Comorbidity Index,23 CHA2DS2VASc score
24 as a
measure of stroke risk, and HAS-BLED score25 as a measure
of bleeding risk (see score definitions in Tables S2 and S3).
Statistical Analysis
We provided descriptive summaries of patient baseline
characteristics at the time of index OAC prescription
redemption and at the 180-day landmark as proportions
for discrete variables and means and SDs for continuous
variables, and stratified according to treatment regimen.
Because the risk of dementia is strongly associated with age,
ie, the hazard is expected to change as a function of age, we
conducted all analyses stratified by age group (categorized
as 60–69 years, 70–79 years, and 80 years and older) at
the time of the 180-day landmark. To compare the risk of
dementia among NOAC users with warfarin (reference) users
within each age group, we calculated cause-specific hazard
ratios (HRs) using Cox regression models. Failure curves
were used to depict how dementia risk evolved over time.
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Specifically, we used the Aalen-Johansen estimator to
calculate absolute risk of dementia in each age group,
taking into account the competing risk of death.24 Study end
points were examined using the full follow-up period
available.
To allow an unbiased comparison of NOAC users and
warfarin users, we applied an inverse probability of treatment
weighting approach. With this approach, stabilized weights
were derived to obtain estimates representing population
average treatment effects with optimal balance between the
treatment populations within each age group.26,27 We used
generalized boosted models based on up to 10 000 regres-
sion trees to obtain the propensity for receiving a treatment
allocation, as previously performed.20,28 The covariates for the
regression trees included indicators of comorbidity and
concomitant medical treatment at the time of study inclusion
(eg, first OAC prescription redemption) (see Table S4 for
specification of variables). The examined treatment regimens
should be contrasted on comparable populations and any
patient must have positive probability for any treatment within
all covariate strata (positivity assumption). We therefore
required substantial overlap between the propensities for
each treatment group to ensure exchangeability (under
assumption of correct model specification), and inspected
the distribution of weights to detect extreme values, which
may indicate violation of the positivity assumption.29 In
agreement with best methodological practice, this assump-
tion was assessed by graphical inspection of the weight
distributions.30 Additionally, balance between treatment pop-
ulations was evaluated by standardized differences of all
baseline covariates, using a threshold of 0.1 to indicate
imbalance.31
Sensitivity Analyses
We performed 4 sensitivity analyses to ascertain the robust-
ness of our findings. First, given the assumed induction period
in the development of dementia, we repeated the analyses
excluding the initial 365 days following the date of OAC
prescription (eg, using a 365-day landmark). Second, because
duration of AF may affect dementia development, we
conducted an analysis stratified by incident versus noninci-
dent AF. Third, to study potential selective prescribing of
reduced-dose NOACs to patients with prodromal symptoms of
dementia, we conducted analyses stratified by NOAC dose
(standard versus reduced dose); warfarin is only available in
2.5-mg dose tablets in Denmark and dosed individually. Last,
to evaluate the presence of residual confounding, we
conducted analyses on “falsification outcomes,” ie, outcomes
that a priori should not represent a causal effect of
treatment.32 For this analysis, we used hospital diagnoses
of pneumonia and diagnoses of urinary tract infection
ascertained by prescriptions claim for trimethoprim, pivme-
cillinam, sulfamethizole, or nitrofurantoin, which are used
specifically for urinary tract infection treatment in Denmark.33
We recalculated all weights in all supplementary and sensi-
tivity analyses and inspected weight distributions and stan-
dardized differences. All standardized differences were below
the 0.1 threshold, with exception of the estimates for renal
dysfunction in the analyses of patients with reduced-dose
NOAC, where the standardized differences ranged from 0.19
to 0.26 for NOAC versus warfarin users stratified by age
group.
Point estimates were reported with 95% CIs and a P<0.05
was considered statistically significant. All analyses were
performed using STATA/MP version 15 (StataCorp) and R
version 3.3.3 (The R Foundation).
Results
Between August 11, 2011, and December 31, 2016, we
identified 114 824 new users of OAC treatment aged
60 years and older. After exclusions, the study population
comprised 34 683 incident OAC users with hospital-diag-
nosed AF. Of these, 11 178 (32%) were aged 60 to 69 years,
13 513 (39%) were 70 to 79 years, and 9992 (29%) were
80 years and older (Figure 1). Overall, 60% of patients
were NOAC users and 40% were warfarin users, and this
distribution was generally similar across the 3 age groups.
Conversely, the proportion of NOAC users given a reduced
dose increased considerably with increasing age, from 9.0%
in patients aged 60 to 69 years, to 23.0% in patients aged
70 to 79 years and 73.7% in patients 80 years and older.
Table 1 provides patient characteristics by age and treat-
ment regimen at index OAC prescription before applying
propensity weighting. Mean CHA2DS2-VASc, HAS-BLED, and
Charlson Comorbidity Index scores increased with increasing
age but varied little by treatment regimen. Recorded ICD
codes of smoking-, alcohol-, or drug abuse–related diagnoses
were infrequent across all age groups and treatment
regimens.
180-Day Landmark Populations
A total of 956 patients died before the date of the 180-day
landmark and 110 were diagnosed with dementia, leaving
33 617 patients in the 180-day landmark population (Fig-
ure 1). Table S4 and Figure S1 illustrates the change in
patient characteristics from index OAC prescription to the
180-day landmark. The prevalence of most hospital-diagnosed
comorbidity changed little, with slight increases in mean risk
and comorbidity scores. However, diagnoses of heart failure
increased markedly over the landmark period. Comedication
DOI: 10.1161/JAHA.118.011358 Journal of the American Heart Association 4
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use also increased, in particular cardiovascular medicine such
as loop diuretics, digoxin, and b-blockers.
After weighing the study populations using the inverse
probability of treatment weighting method, most baseline
standardized differences were below the 0.1 threshold,
indicating that the weighted treatment regimens were com-
parable within each age group with regard to measured
covariates (Figure S2). Inspection of individual propensity
score distributions showed sufficient overlap between treat-
ment populations in order to obtain a valid comparison
(Figure S3).
Dementia Risk
The mean follow-up was 3.4 years (SD 1.6); 3.7 for patients
aged 60 to 69 years (3.4 years for NOACs and 4.3 years for
warfarin), 3.4 for patients aged 70 to 79 years (3.1 years for
NOACs and 3.9 years for warfarin), and 2.9 for patients
80 years and older (2.7 years for NOACs and 3.3 years for
warfarin). Figure 2 displays cumulative incidence of dementia
by treatment regimen and age. During follow-up, 41 patients
aged 60 to 69 years developed dementia, 276 patients aged
70 to 79 years developed dementia, and 441 patients
80 years and older developed dementia (Table 2).
Among patients aged 60 to 69 years, rates of dementia
were nonsignificantly lower between NOAC versus warfarin
users (0.11 per 100 person-years versus 0.12); weighted HR
at full follow-up, 0.92 (95% CI, 0.48–1.76) (Table 2,
Figure 3). For patients aged 70 to 79 years, NOAC use
was also associated with lower rates of dementia compared
with warfarin use (0.64 per 100 person-years versus 0.78
per 100 person-years; weighted HR, 0.86 [95% CI, 0.89–
1.09]), whereas NOAC use was associated with increased
rates of dementia compared with warfarin use (2.16 per 100
person-years versus 1.70 per 100 person-years, weighted
HR, 1.31 [95%, 1.07–1.59]) in patients 80 years and older
(Figure 3).
Similar patterns were also evident for the specific demen-
tia subtypes, although there were few events yielding
imprecise estimates with wide CIs (Figure 3), and when using
a 365-landmark, stratifying by incident versus nonincident AF,
or restricting the analyses alternately to patients with
standard or reduced doses of NOACs.
Falsification End Points
Analyses of the treatment-associated falsification end points
yielded weighted hazard rates around the null for most
comparisons, indicating that the a priori hypothesis of neutral
associations were fulfilled (Figure 3, Table S5).
Discussion
In this nationwide cohort study investigating OAC-naive
patients with nonvalvular AF and no prior neurological
diagnoses, we observed nonsignificantly lower rates of
dementia among NOAC users younger than 80 years relative
to warfarin users, whereas rates were higher among NOAC
users in patients 80 years and older.
114,824 elegible individuals aged 60 years and older with a first 
prescription of NOAC or warfarin in the period August 11, 2011 
to December 31, 2016
1,812 immigrated within 5 years of index date
54,616 individuals without a hospital diagnosis
of atrial fibrillation
1,069 individuals with valvular atrial fibrillation
1,901 individuals with venous thromboembolism 
within 90 days before prescription redemption
14,863 individuals with prior neurological diagnoses
1,038 individuals with prior dementia diagnoses 
or prescription for anti-dementia medications
4,842 individuals without extended usage 
of oral anticoagulant therapy
34,683 individuals enrolled
11,178 aged 60-69 years (39% warfarin, 61% NOAC)
13,513 aged 70-79 years (40% warfarin, 60% NOAC)
9,992 aged 80 years and above (37% warfarin, 63% NOAC)
0-180-day landmark period:
956 individuals died
114 (1.0%) aged 60-69 years
247 (1.8%) aged 70-79 years
595 (6.0%) aged 80 years and above
110 diagnosed with dementia or anamnestic symptoms
12 (0.1%) aged 60-69 years
29 (0.2%) aged 70-79 years
69 (0.7%) aged 80 years and above
33,617 individuals included in the 180-day landmark population
11,052 aged 60-69 years (39% warfarin, 61% NOAC)
13,237 aged 70-79 years (40% warfarin, 60% NOAC)
9,238 aged 80 years and above (37% warfarin, 63% NOAC)
Figure 1. Flowchart of the study population. NOAC indicates
nonvitamin K antagonist oral anticoagulant.
DOI: 10.1161/JAHA.118.011358 Journal of the American Heart Association 5
Atrial Fibrillation and Dementia Søgaard et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on June 21, 2019
Table 1. Patient Characteristics by Age at First OAC Prescription Redemption of OAC-Naive Patients With AF (N=34 683)
Characteristic, % (No.)
60 to 69 y 70 to 79 y 80 y and Older
Warfarin NOAC Warfarin NOAC Warfarin NOAC
No. 4332 6846 5387 8126 3653 6339
Median time from first AF diagnosis to
first OAC prescription, d (IQR)
19 (4–546) 8 (2–438) 12 (4–230) 7 (3–136) 11 (5–162) 9 (4–144)
Dabigatran . . . 46.1 (3156) . . . 39.1 (3178) . . . 32.8 (2078)
Apixaban . . . 28.3 (1940) . . . 32.2 (2618) . . . 39.4 (2496)
Rivaroxaban . . . 25.6 (1750) . . . 28.7 (2330) . . . 27.8 (1765)
Reduced-dose NOAC . . . 9.0 (614) . . . 23.0 (1867) . . . 73.7 (4673)
Hospital stay within 30 d 66.4 (2878) 62.6 (4285) 70.2 (3784) 66.6 (5413) 78.0 (2850) 75.3 (4774)
Women 35.6 (1543) 37.8 (2585) 43.9 (2367) 46.9 (3815) 55.5 (2027) 62.1 (3939)
Mean age (SD) 65.9 (2.7) 65.9 (2.7) 74.9 (2.8) 74.7 (2.9) 85.1 (3.8) 86.1 (4.4)
Comorbidity
Mean CHA2DS2-VASc score (SD) 2.2 (1.2) 2.1 (1.2) 3.3 (1.3) 3.1 (1.2) 4.0 (1.2) 3.9 (1.1)
Mean HAS-BLED score (SD) 2.0 (1.1) 1.9 (1.0) 2.5 (0.9) 2.4 (0.9) 2.6 (0.9) 2.4 (0.9)
Mean Charlson Comorbidity
Index score (SD)
0.9 (1.4) 0.8 (1.4) 1.2 (1.6) 1.1 (1.6) 1.2 (1.6) 1.3 (1.6)
Renal dysfunction 6.5 (280) 2.8 (189) 8.7 (471) 4.3 (351) 10.0 (366) 5.1 (323)
Myocardial infarction 11.0 (475) 8.0 (550) 15.0 (809) 10.2 (829) 17.1 (625) 13.0 (825)
Heart failure 16.9 (731) 11.2 (765) 21.1 (1136) 15.5 (1263) 34.2 (1250) 28.0 (1774)
Peripheral arterial disease 6.1 (265) 5.0 (341) 10.4 (562) 7.5 (608) 10.5 (383) 8.8 (559)
Vascular disease 15.7 (679) 12.1 (830) 22.4 (1204) 16.2 (1318) 24.9 (908) 19.8 (1254)
Diabetes mellitus 14.2 (615) 11.1 (761) 13.6 (731) 11.6 (940) 11.6 (422) 10.8 (686)
Hyperlipidemia 15.7 (678) 12.8 (877) 17.4 (937) 14.3 (1164) 13.1 (478) 10.6 (672)
Hypertension 60.7 (2629) 58.3 (3992) 65.0 (3504) 62.2 (5057) 69.1 (2525) 65.0 (4119)
Cancer 4.6 (198) 3.6 (246) 6.8 (365) 5.8 (472) 6.3 (229) 6.1 (385)
Chronic pulmonary disease 12.2 (530) 11.1 (760) 17.2 (926) 15.8 (1280) 17.1 (625) 17.4 (1103)
Prior bleeding 10.3 (446) 9.5 (651) 13.0 (700) 13.1 (1063) 15.6 (569) 14.7 (931)
Depression 1.4 (60) 1.3 (91) 1.5 (79) 1.7 (140) 2.2 (80) 2.9 (183)
Hospital-diagnosed obesity 10.2 (440) 9.6 (657) 8.0 (429) 7.8 (634) 4.8 (177) 4.8 (305)
Smoking-related diagnoses 4.4 (192) 4.7 (323) 4.7 (254) 5.0 (404) 2.7 (99) 3.7 (236)
Alcohol-related abuse 4.3 (186) 4.6 (314) 2.5 (132) 3.2 (258) 1.1 (42) 1.2 (78)
Drug-related abuse 0.2 (7) 0.2 (11) 0.1 (8) 0.2 (15) 0.1 (5) 0.2 (12)
Comedications
Clopidogrel 3.8 (164) 2.5 (173) 4.5 (241) 3.7 (298) 4.6 (167) 4.5 (284)
Aspirin 39.2 (1696) 34.1 (2337) 45.8 (2466) 38.0 (3085) 49.8 (1821) 44.5 (2821)
Loop diuretics 16.9 (734) 11.2 (768) 21.2 (1143) 15.7 (1272) 34.2 (1250) 28.1 (1779)
Nonloop diuretics 33.0 (1428) 32.6 (2233) 39.7 (2137) 38.1 (3093) 45.4 (1658) 42.1 (2669)
Digoxin 5.5 (238) 3.6 (248) 6.6 (358) 4.8 (387) 9.2 (337) 8.5 (541)
b-Blockers 47.0 (2035) 38.8 (2656) 44.2 (2380) 37.9 (3078) 45.3 (1655) 37.8 (2395)
Calcium channel blockers 29.4 (1275) 27.0 (1848) 32.5 (1751) 31.1 (2529) 37.2 (1358) 32.7 (2075)
Verapamil 4.0 (172) 3.1 (212) 3.0 (162) 2.3 (186) 2.4 (86) 2.4 (153)
Renin-angiotensin inhibitors 45.2 (1960) 44.3 (3034) 47.9 (2578) 47.2 (3839) 50.5 (1843) 46.0 (2915)
Continued
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Comparison With Previous Studies
In the absence of disease-modifying treatments for most
forms of dementia, any means to prevent or delay its onset is
of major clinical and social importance.34 Accumulating
evidence suggests an association between AF and dementia
via various pathways including occurrence of overt or silent
strokes, lower cardiac output in AF leading to cerebral
hypoperfusion, and/or presence of shared risk factors for AF
and dementia.4–8,35
Nevertheless, it is less clear to what extent dementia
development in AF is affected by OAC treatment. Prior studies
have indicated that the quality of management of warfarin
therapy as measured by TTR is associated with risk of
dementia.6,11 The hypothesis being that periods of suprather-
apeutic or subtherapeutic anticoagulation predispose patients
to microbleeds and microthrombi, which may eventually lead
to dementia; hence, dementia could be considered a potential
long-term complication of warfarin therapy. This line of
thinking represents a challenging clinical situation with a
therapy used to prevent life-threatening strokes that poten-
tially lead to long-term cognitive defects. On the other hand, a
recent Swedish cohort study found a 29% lower relative risk of
dementia in patients with AF treated with OACs compared
with patients with AF without OAC treatment,13 suggesting
that it is likely not anticoagulation per se but the extent of
exposure to overcoagulation and/or undercoagulation that
could confer an increased risk of dementia.
A central question is whether optimized treatment of AF
can prevent or delay the onset of dementia. It has been
hypothesized that NOACs could play a role in reducing the
risk of cognitive impairment and dementia in patients with AF
but the available evidence is sparse and equivocal.13,14 In a
US cohort of patients receiving long-term anticoagulation
with either NOACs or warfarin, Jacobs et al14 reported a lower
rate of dementia in NOAC users (0.3%. versus 0.7%).14
However, the duration of follow-up was short (median
309 days for warfarin users versus 185 days for NOAC
users), and the study population included patients with prior
OAC use as well as stroke. Using data from 2 large US claims
databases, Chen et al36 recently compared the incidence of
dementia in patients with AF initiating treatment with
different OACs. Based on 6 sets of 1:1 pairwise propensity
score–matched comparisons of different OAC regimens, the
authors concluded that NOACs were associated with a lower
incidence of dementia compared with warfarin, with HRs
ranging from 0.73 to 0.79 according to choice of NOAC. In
line with our findings, Friberg et al13 found comparable rates
of dementia in Sweden when comparing propensity-matched
cohorts of warfarin users and NOAC users (HR, 0.97; 95% CI,
0.67–1.40).
By including a large nationwide cohort of OAC-naive
patients without previous neurological diagnoses, our study
extends these previous studies. Our finding of comparable
rates of dementia across treatment regimens may poten-
tially not be generalizable to other populations given the
presumably better quality of anticoagulation control with
warfarin in both the Danish and the Swedish settings with
Table 1. Continued
Characteristic, % (No.)
60 to 69 y 70 to 79 y 80 y and Older
Warfarin NOAC Warfarin NOAC Warfarin NOAC
Statin 37.4 (1619) 35.3 (2415) 43.3 (2333) 38.6 (3139) 34.4 (1256) 30.3 (1921)
NSAIDs 23.3 (1008) 23.9 (1639) 23.1 (1242) 23.3 (1895) 18.9 (691) 18.4 (1169)
AF indicates atrial fibrillation; IQR, interquartile range; NOAC, nonvitamin K antagonist oral anticoagulant; NSAIDs, nonsteroidal anti-inflammatory drugs; OAC, oral anticoagulant.
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Figure 2. Propensity-weighted cumulative risk of dementia by
age and treatment regimen since the 180-day landmark. NOAC
indicates nonvitamin K antagonist oral anticoagulant.
Table 2. Number of Events and Crude and Weighted Rates of
Dementia Per 100 Person-Years by Age and Treatment
Regimen
Outcome
Age 60 to 69 y Age 70 to 79 y Age 80 y and Older
NOAC Warfarin NOAC Warfarin NOAC Warfarin
No. of events 20 21 133 143 279 162
Crude rate 0.11 0.12 0.64 0.80 2.16 1.65
Weighted rate 0.11 0.12 0.64 0.78 2.16 1.70
NOAC indicates nonvitamin K antagonist oral anticoagulant.
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TTR >70% in routine clinical care37,38 compared with (for
example) a TTR of 54% among 138 319 patients treated in
US physician practices.39 A randomized trial comparing the
incidence of dementia in patients with AF randomized to
either warfarin or dabigatran was initiated in 2017 with
estimated completion in 2021 (ClinicalTrials.gov identifier:
NCT03061006).
Study Strengths
The registry databases facilitated our implementation of a
large well-defined, nationwide, population-based cohort of
patients with nonvalvular AF initiating OAC treatment during
2011 through 2016. The tax-supported healthcare system for
the entire Danish population includes free access to medical
care and partial reimbursement of prescribed medications,15
leading to minimal disparity in access to healthcare services
in this study. Also, analyses of the treatment-associated
falsification end points found that the a priori hypothesis of
neutral associations was fulfilled.
Study Limitations
There are also limitations to our study. Most importantly, data
were drawn from administrative registries. Because of the
observational nature of our study, residual or unmeasured
confounding is likely to persist. For instance, patients with
cognitive impairment have been shown tohave poorer control of
their international normalized ratio,40 and we cannot exclude
that the increased risk of dementia associated with NOACs in
patients 80 years and older could represent channeling of
NOACs toward patients with prodromal or undiagnosed preva-
lent dementia. We did not have access to information on
treatment adherence and TTR among warfarin users, nor did we
have clinical data on the severity and control of comorbidities or
laboratory (eg, renal function), anthropometric, or socioeco-
nomic data, which could have improved our ability to control
confounding.Another limitation is the relatively shortdurationof
follow-up when considering the induction period for dementia
development, and our follow-up period (mean 3.4 years) may
not have been long enough to detect a differential effect of
treatment regimen on dementia development. Furthermore, we
lacked results of diagnostic brain imaging and objective
measures of cognitive function. The diagnosis of dementia has
a high positive predictive value, whereas the sensitivity is
unknown.22
Conclusions
In this propensity-weighted Danish nationwide cohort of OAC-
naive patients with AF with no prior neurological diagnoses,
there was no clinically meaningful difference in dementia
development between the majority of users of NOAC or
warfarin, apart from those 80 years and older, where a higher
risk was noted in NOAC users. Potential residual confounding
related to selective prescribing and unobserved comorbidities
warrant cautious clinical interpretation of our findings.
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Figure 3. Forest plots of propensity-weighted study outcomes by age and treatment regimen. AF indicates atrial fibrillation; NOAC, nonvitamin
K antagonist oral anticoagulant.
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Table S1. Definitions on comorbidity and concomitant medication according to ICD-10 
codes and ATC-codes. 
Disease ICD-8 codes ICD-10 codes ATC-code 
Study population 
AF 42793 42794 I48 
Exposure 
Warfarin B01AA03 
Dabigatran B01AE07 
Rivaroxaban B01AF01 
Apixaban B01AF02 
Outcome 
Dementia 
    Alzheimer’s disease 290.10, 290.09 F00, G30 
    Vascular dementia 293.09, 293.19 F01 
    Other dementia 094.19, 290.11-290.19 F02-F03, F10.73-F19.73, 
G23.1, G31.0A, G31.0B, 
G31.1, G31.8B, G31.8E, 
G31.85 
Exclusion criteria 
PE and/or DVT within 90 days 
before index date 
Valvular AF 
Mitral stenosis I05 
Mechanical heart valve Z952 Z953 Z954 
Ischemic stroke 433-434 I63 
Hemorrhagic 
stroke/intracerebral bleeding 
430 431 I60 I61 I62 
Unspecified stroke 436 I64 
Transient ischemic disease 43509 43599 G45 
other cerebrovascular disease 432, 437, 438 I62, 165-169, G46 
Traumatic intracranial bleeding S063C S064 S065 S066 
Hemiplegia 344 G81, G82 
Dementia 094.19, 290.09-290.19, 
292.09, 293.09, 293.19  
F00-F03, G30, F1x.73 
series (F10.73, F1173, 
F1273, F1373, F1473, 
F1573, F1673, F1873- 
F19.73), G23.1, G31.0, 
G31.0A, G31.0B, G31.1, 
G31.8B, G31.8E, G31.85 
Cognitive impairment - F06 
Amnestic syndromes 291.19 F04, F04.9, F05.1, F10.6, 
F18.6, F19.6  
Head trauma 850.99, 851.29-854.99, 
800.99-801.09, 803.99  
S06.0, S06.1-S06.9, 
S02.0-S02.1, S02.7, 
S02.9  
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Comorbidity (shared risk 
factors) 
Underlying vascular diseases 
Myocardial infarction 410 I21 I23 
Heart failure 42709 42710 42711 
42719 42899 78249 
I110 I130 I132 I50 
Peripheral arterial disease 440 441 442 443 444 445 I702 I703 I704 I705 I706 
I707 I708 I709 I71 I739 
I74 
Diabetes 24900 24909 25008 
25009 
E10 E11 A10 
Hyperlipidemia / 
hypercholesterolemia 
272.00-272.09 
279.00 
279.01 
E780-E782 
E784 
E785 
Hypertension See specified 
definition 
belowa 
Other comorbidities 
Cancer C 
Renal disease 
Bleeding 
Smoking-related diagnoses 
Chronic pulmonary disease 490-493, 515-518 J40-J47, J60-J67, J68.4, 
J70.1  
Diagnosis of problems related 
to active smoking 
- Z720A, Z720E 
Smoking prevention 
counselling or smoking 
cessation intervention 
- Treatment codes: 
BQFT01, BQFS01 
Current or former smoking 
status 
- Administrative procedure 
codes: ZZP01A1A, 
ZZP01A1B2, ZZP0020 
Hospital diagnosed obesity 277 E65-E68 
Depression 296.09, 296.29, 296.99, 
298.09, 300.49, 300.19  
F32, F33 
Substance abuse diagnoses 
and related comorbidities  
Drug-related abuse 
Opioids 304.09, 304.19 F11.0-F11.9 
Cannabis 304.59 F12.0-F12.9 
Sedatives/hypnotics 304.29, 304.39 F13.0-F13.9 
Cocaine 304.49 F14.0-F14.9 
Other stimulants 304.69 F15.0-F15.9 
Hallucinogens 304.79 F16.0-F16.9 
Other and multiple drugs 304.89, 304.99 F18.0-F19.9 
Alcohol-related abuse 
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Alcohol psychosis, and alcohol 
abuse syndrome  
291.09-291.99, 303.09-
303.99  
F10.2-F10.9 
Alcohol related diseases 571.09, 571.10, 577.10, 
979.59 
G31.2, G62.1, G72.1, 
I42.6, K29.2, K70, 
K86.0, T50.0A, Z72.1 
Co-medications 
Diabetes mellitus A10 
Clopidogrel B01AC04 
Aspirin B01AC06 
Thienopyridines (clopidogel, 
tricagrelor, prasugrel)  
B01AC04 
B01AC24 
B01AC22 
Loop diuretics C03C 
Digoxin C01AA05 
Dronedarone C01BD07 
Hypertension C02 
Non-loop diuretics C02DA C02L 
C03A C03B 
C03D C03E 
C03X C07C 
C07D C08G 
C09BA C09DA 
C09XA52  
Congestive heart failure C03C 
Beta blocker C07 
Calcium channel blocker C07F C08 
C09BB C09DB 
Verapamil C08DA01 
Renin-angiotensin inhibitor 
(ARB or ACE inhibitor)  
C09 
Statins C10 
NSAIDs M01A 
Dementia medications 
Anti-dementia medications N06D 
     Donepezil N06DA02 
     Rivastigmin N06DA03 
     Galantamin N06DA04 
     Memantin N06DX01 
aWe identified subjects with hypertension from combination treatment with at least two of the following classes 
of antihypertensive drugs: 
I· Alpha adrenergic blockers (C02A, C02B, C02C) 
II· Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, 
C09XA52) 
III· Vasodilators (C02DB, C02DD, C02DG, C04, C05)  
IV· Beta blockers (C07) 
V· Calcium channel blockers (C07F, C08, C09BB, C09DB) 
VI· Renin-angiotensin system inhibitors (C09) 
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Table S2. Risk score definitions. 
Risk score 
Points 
if present 
CHA2DS2VASc* 
   Congestive heart failure or Left Ventricular Dysfunction 1 
   Hypertension 1 
   Age ≥ 65 years 1 
   Age ≥ 75 years 1 
   Diabetes mellitus 1 
   Stroke (ischemic stroke, transient ischemic disease or systemic embolism) 2 
   Vascular disease (myocardial infarction, peripheral arterial disease, or aortic 
plaque) 
1 
   Sex category (female) 1 
HAS-BLED† 
   Hypertension 1 
   Abnormal renal function 1 
   Abnormal hepatic function 1 
   Stroke (ischemic stroke or transient ischemic attack) 1 
   Bleeding 1 
   Labile international normalized ratio£ 1 
   Elderly age (≥ 65 years) 1 
   Drugs (aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs) 1 
   Alcohol intake 1 
*Reflects stroke risk in atrial fibrillation patients not in anticoagulant therapy (Lip GYH, Nieuwlaat R, Pisters R,
Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial 
fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. (Chest
2010;137:263-72)
†Reflects bleeding risk in atrial fibrillation patients undergoing anticoagulant therapy (Pisters R, Lane DA, 
Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year 
risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100). 
£Not included due to unavailable information 
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Table S3. Definition of Charlson Comorbidity Index. 
Weight Condition ICD-10 ICD-8 
1 Myocardial infarction I21 I22 I23 410 
1 Congestive heart 
failure  
I50 I110 I130 I132 42709 42710 42711 
42719 42899 78249 
1 Peripheral vascular 
disease  
I70 I71 I72 I73 I74 I77 440 441 442 443 444 
445 
1 Cerebrovascular 
disease  
I60 I61 I62 I63 I64 I65 I66 
I67 I68 I69 G45 G46 
430 431 432 433 434 
435 436 437 438 
1 Dementia F00 F01 F02 F03 F051 G30 29009 29010 29011 
29012 29013 29014 
29015 29016 29017 
29018 29019 29309 
1 Cronic pulmonary 
disease  
J40 J41 J42 J43 J44 J45 J46 
J47 J60 J61 J62 J63 J64 J65 
J66 J67 J684 J701 J703 J841 
J920 J961 J982 J983 
490 491 492 493 515 
516 517 518 
1 Connective tissue 
disease  
M05 M06 M08 M09 M30 
M31 M32 M33 M34 M35 
M36 D86 
712 716 734 446 
13599 
1 Ulcer disease K221 K25 K26 K27 K28 53091 53098 531 532 
533 534 
1 Mild lever disease B18 K700 K701 K702 K703 
K709 K71 K73 K74 K760 
571 57301 57304 
1 Diabetes Mellitus E10 E11 E12 E13 E14 O240 
O241 O242 O243 O245 
O246 O247 O248 O249 
H360 
249 250 
2 Hemiplegia G81 G82 344 
2 Moderate to severe 
renal disease 
I12 I13 N00 N01 N02 N03 
N04 N05 N07 N11 N14 N17 
N18 N19 Q61  
403 404 580 581 582 
583 584 59009 59319 
7531 792 
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2 Diabetes with chronic 
complications  
E102 E103 E104 E105 E106 
E107 E108 E112 E113 E114 
E115 E116 E117 E118 
24901 24902 24903 
24904 24905 24908 
25001 25002 25003 
25004 25005 25008 
2 Any tumor C0 C1 C2 C3 C4 C5 C6 C70 
C71 C72 C73 C74 C75 
14 15 16 17 18 190 
191 192 193194 
2 Leukemia C91 C92 C93 C94 C95 204 205 206 207 
2 Lymphoma C81 C82 C83 C84 C85 C88 
C90 C96  
200 201 202 203 
27559 
3 Moderate to severe 
liver disease 
B150 B160 B162 B190 K704 
K72 K766 I85 
07000 07002 07004 
07006 07008 57300 
4560 
6 Metastatic solid tumor C76 C77 C78 C79 C80 195 196 197 198 199 
6 AIDS B21 B22 B23 B24 07983 
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.
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Table S4. Patient characteristics by age at time of index oral anticoagulant prescription claim and at the 180-day landmark before propensity-
weighting.  
60-69 years 70-79 years
80 years and older 
Characteristic, % (N) 
Index 
180-day 
landmark 
Index 
180-day 
landmark 
Index 
180-day 
landmark 
N 11052 11052 13237 13237 9328 9328 
Female sex 37.0 (4085) 37.0 (4085) 45.7 (6046) 45.7 (6046) 59.8 (5581) 59.8 (5581) 
Mean age (sd)* 65.9 (2.7) 65.9 (2.7) 74.8 (2.9) 74.8 (2.9) 85.6 (4.1) 85.6 (4.1) 
Mean CHA2DS2-VASc score (sd) 2.1 (1.2) 2.3 (1.2) 3.1 (1.3) 3.3 (1.3) 4.0 (1.1) 4.1 (1.2) 
Mean HAS-BLED score (sd) 1.9 (1.0) 2.1 (1.0) 2.4 (0.9) 2.5 (0.9) 2.5 (0.9) 2.5 (0.9) 
Mean Charlson Comorbidity score 
(sd) 
0.8 (1.4) 0.8 (1.4) 1.1 (1.5) 1.1 (1.5) 1.2 (1.6) 1.2 (1.6) 
Myocardial infarction* 9.1 (1011) 9.5 (1047) 12.0 (1587) 12.4 (1648) 14.2 (1320) 14.7 (1367) 
Heart failure* 13.0 (1440) 26.0 (2868) 17.2 (2276) 33.1 (4382) 29.0 (2708) 50.5 (4709) 
Peripheral arterial disease* 5.3 (586) 6.0 (659) 8.5 (1120) 9.1 (1210) 9.0 (839) 9.8 (912) 
Vascular disease* 13.4 (1478) 14.2 (1570) 18.4 (2436) 19.4 (2564) 20.9 (1953) 22.0 (2051) 
Diabetes* 12.1 (1342) 13.4 (1478) 12.1 (1600) 13.2 (1745) 10.9 (1013) 11.5 (1069) 
Hyperlipdemia* 13.9 (1534) 15.8 (1744) 15.4 (2042) 16.8 (2228) 11.5 (1075) 12.3 (1151) 
Hypertension* 59.1 (6533) 66.2 (7312) 63.2 (8366) 68.6 (9074) 66.5 (6207) 70.6 (6585) 
Cancer 3.7 (412) 5.2 (576) 5.8 (773) 8.0 (1053) 5.9 (548) 8.5 (794) 
Chronic pulmonary disease 11.2 (1240) 12.5 (1381) 16.0 (2119) 17.6 (2326) 16.4 (1534) 17.9 (1670) 
Liver disease 0.4 (40) 0.4 (45) 0.3 (36) 0.3 (41) 0.2 (17) 0.2 (19) 
Renal dysfunction 4.1 (453) 4.8 (532) 5.8 (774) 7.0 (921) 6.7 (622) 8.1 (755) 
Prior bleeding 9.6 (1065) 10.9 (1201) 12.9 (1709) 14.5 (1920) 14.9 (1393) 16.7 (1558) 
Depression 1.3 (144) 1.4 (156) 1.5 (205) 1.7 (225) 2.5 (235) 3.0 (284) 
Hospital diagnosed obesity 9.8 (1078) 10.8 (1195) 7.8 (1030) 8.3 (1095) 4.8 (444) 4.9 (460) 
Smoking-related diagnoses* 4.4 (486) 5.3 (587) 4.7 (620) 6.1 (811) 3.1 (293) 4.3 (399) 
Alcohol-related abuse* 4.4 (483) 4.6 (505) 2.8 (372) 3.0 (391) 1.1 (104) 1.2 (112) 
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Drug-related abuse* 0.2 (17) 0.2 (17) 0.2 (22) 0.2 (23) 0.2 (14) 0.2 (14) 
Clopidogrel 3.0 (330) 5.0 (554) 3.9 (522) 6.7 (881) 4.6 (426) 7.0 (657) 
Aspirin 36.0 (3981) 37.4 (4132) 40.9 (5413) 41.8 (5534) 46.2 (4314) 46.0 (4294) 
Loop diuretics 13.1 (1446) 26.0 (2873) 17.3 (2292) 33.2 (4394) 29.1 (2713) 50.5 (4713) 
Non-loop diuretics 32.7 (3612) 39.4 (4358) 38.7 (5117) 43.4 (5742) 43.2 (4028) 47.4 (4417) 
Digoxin 4.2 (464) 22.1 (2443) 5.3 (708) 25.3 (3354) 8.6 (798) 34.0 (3171) 
  Beta blocker 41.9 (4630) 82.4 (9111) 40.2 (5322) 80.0 (10586) 40.7 (3792) 75.3 (7024) 
  Calcium channel blocker 27.9 (3089) 32.4 (3580) 31.6 (4185) 35.0 (4627) 34.5 (3214) 36.3 (3390) 
Verapamil 3.4 (379) 6.6 (729) 2.6 (341) 5.0 (663) 2.4 (221) 3.7 (344) 
Renin-angiotensin inhibitor 44.6 (4933) 54.8 (6055) 47.4 (6269) 55.8 (7385) 47.8 (4455) 54.4 (5070) 
Statins 36.0 (3984) 42.8 (4734) 40.5 (5363) 45.4 (6009) 32.0 (2986) 34.5 (3222) 
*Included in the propensity score
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Table S5. Crude and weighed hazard ratios for the association between exposure and 
falsification endpoints. 
Falsification endpoint 
60-69 years
Hazard ratio (95% CI) 
70-79 years
Hazard ratio (95% CI) 
80 years and older 
Hazard ratio (95% CI) 
Pneumonia 
Crude analysis 0.79 (0.69-0.91) 0.91 (0.82-1.01) 0.97 (0.88-1.06) 
Weighted analysis 0.83 (0.72− 0.96) 0.97 (0.87− 1.07) 0.96 (0.87− 1.06) 
Urinary tract infection 
Crude analysis 0.92 (0.84-1.01) 0.89 (0.82-0.96) 1.07 (0.99-1.16) 
Weighted analysis 0.92 (0.83− 1.01) 0.88 (0.82− 0.95) 1.01 (0.93− 1.09) 
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Figure S1. Change in patient characteristics by age from the time of index oral anticoagulant 
prescription claim (day 0) to the 180-day landmark before propensity-weighting visualized by 
signed standardized differences. 
Patients aged 60-69 years 
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Patients aged 70-79 years
Patients aged 80 years and older 
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Figure  S2. Plot of maximum of pairwise standardized differences for patient characteristics of 
NOAC users and warfarin users at the 180-day landmark stratified by age before and after applying 
propensity weights (IPTW).  
Patients aged 60-69 years 
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Patients aged 70-79 years 
Patients aged 80 years and older D
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Figure S3. Propensity score distributions for warfarin and NOAC by age group. Overall 
60-69 years 70-79 years  80 years and older 
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Standard dose NOAC 
60-69 years 70-79 years  80 years and older 
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Reduced dose NOAC 
60-69 years 70-79 years  80 years and older 
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